Results 251 to 260 of about 395,539 (294)

Treatment of cognitive impairment in patients with cerebral infarction in the internal carotid arteries circulation system: results of a multicentre, randomized, double-blind, placebo-controlled clinical trial

open access: diamond
Д. Р. Хасанова   +6 more
openalex   +2 more sources

A Global Transcriptomic Analysis Reveals Body Weight‐Specific Molecular Responses to Chronic Orange Juice Consumption in Healthy Individuals

open access: yesMolecular Nutrition &Food Research, EarlyView.
This study aimed to investigate the molecular pathways involved in the health benefits of chronic orange juice (OJ) consumption through global transcriptomic approach in peripheral blood mononuclear cells (PBMCs). Healthy volunteers consumed 500 mL of OJ daily for 60 days.
Layanne Nascimento Fraga   +6 more
wiley   +1 more source

Acute hemichorea‐hemiballism as the initial sign of cortical cerebral infarction: A case report

open access: yesNeuroprotection, EarlyView.
Abstract Hemichorea‐hemiballism is classically associated with the contralateral basal ganglia, particularly involving the putamen and subthalamic nucleus, whereas cortical involvement remains a rare etiology. In this case, we present a patient with acute hemichorea‐hemiballism secondary to multiple cortical infarcts demonstrated by neuroimaging.
Jin Xiong   +5 more
wiley   +1 more source

Microglia Display Altered Spatial Morphology and Proteome After Stroke

open access: yesPROTEOMICS, EarlyView.
ABSTRACT Microglia are abundantly distributed throughout the central nervous system (CNS) to play critical roles in neural development and homeostasis, and act as immune sentinels to constantly monitor their surrounding neural environment. Given their high reactivity to brain insults, we hypothesised that the cerebral microenvironment altered by ...
Brooke J. Wanrooy   +10 more
wiley   +1 more source

Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Asundexian is a potent, selective, and reversible inhibitor of activated clotting Factor XI currently under development for secondary prevention of recurrent ischemic stroke in the ongoing Phase III OCEANIC‐STROKE study (NCT05686070). Here, we report the development of a population pharmacokinetic (popPK) model for asundexian.
Ashraf Yassen   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy